B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Duloxetine

A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.

993 PubMed studies analyzed ยท 369 RCTs ยท Evidence Score: 70.7

Research Domains

Duloxetine has been studied across 17 research domains including ๐ŸŒค๏ธ Mood & Depression, ๐Ÿ’Š Pain, ๐Ÿง˜ Stress & Anxiety, ๐Ÿ˜ด Sleep, ๐Ÿฆด Bone & Joint. The primary research focus is ๐ŸŒค๏ธ Mood & Depression with 51% of studies addressing this area.

Loading evidence profile...

This evidence profile for Duloxetine is generated deterministically from 993 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: v20260227-01. Patent pending (EVE-PAT-2026-001). ยฉ 2026 Organiq Sweden AB.